A biosimilar is a biologic medicine that is highly similar to an FDA-approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. Produced from living cells, biosimilars undergo rigorous analytical and clinical evaluation to ensure comparable performance and therapeutic effect.
This CME presentation will explore the evolving role of biosimilars in osteoporosis care for both men and women. Faculty will review the science behind biosimilars, current and emerging options, and key clinical considerations for integrating them into treatment plans for patients at high risk for fracture. The session will address efficacy, safety, regulatory perspectives, and practical implications for improving access and optimizing outcomes. Real-world patient cases will illustrate when and how biosimilars may be effectively applied in clinical practice.
Schedule |
|
| * Times are EST | |
| 12:45 PM | Registration and Boxed Lunches |
| 01:00 PM | Welcome, Disclosure, Supporter Acknowledgement |
| 01:05 PM |
Understanding Biosimilars in Osteoporosis
Biosimilars vs Biologics: Increasing Bone Mass |
| 01:50 PM | Closing Comments, Audience Q&A |
| 02:00 PM | Adjourn |
Aliya Khan, MD, FRCPC, FACP, FACE
Professor of Clinical Medicine
Divisions Endocrinology and Metabolism and Geriatrics
Director, Fellowship in Metabolic Bone Disease
Director, Calcium Disorders Clinic
McMaster University
Oakville, ON, Canada
Azeez Farooki, MD
Attending Physician
Clinical Member
Memorial Sloan Kettering Cancer Center
Associate Clinical Professor
Weill Cornell Medical College
New York, NY
(co-author of the AACE Update Guidelines for Osteoporosis 2020)
EXCEL Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
EXCEL Continuing Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- Explain the concept of biosimilars including regulatory standards, safety, and efficacy data supporting their use in treating osteoporosis
- Apply evidence-based strategies to incorporate biosimilars as alternative treatment options in the management of osteoporosis.
- Evaluate patient case scenarios to determine how biosimilars can serve as a cost-effective alternative to reference biologics, while optimizing therapy selection and improving adherence in osteoporosis management